Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

Biotechnology

Healthcare
$1.43 -2.40%

-$0.04 today

Market cap
$82.18M
Beta
3.23
P/E (TTM)
-2.2
EPS (TTM)
-$0.75
52W Low $1.62High $4.94

Volume 0.60M

Average 1.31M

BDTX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Black Diamond Therapeutics, Inc.NASDAQ: BDTX

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
99.5%— YoY
LTMMar 2026
—— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
99.5%
Year-over-year change
—

Gross Margin vs competitors

How BDTX compares with its peers on the latest reported figures

  • BDTX's FY2025 gross margin of 99.5% is the 2nd highest of the 9 companies compared; the peer median is 67.3%.
BDTX Competitors Peer median
Gross Margin for BDTX and competitors
Company Period LTM level YoY 3-year change
TNYATenaya Therapeutics, Inc.LTM Mar 2026144.9% ——
BDTXBlack Diamond Therapeutics, Inc.FY202599.5% ——
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 202698.3% -1.7 pp-7.0 pp
FENCFennec Pharmaceuticals Inc.LTM Mar 202692.2% +2.0 pp-2.8 pp
CRBUCaribou Biosciences, Inc.LTM Mar 202682.6% +610.6 pp-6.4 pp
ABEOAbeona Therapeutics Inc.LTM Mar 202651.9% —+5.5 pp
IVAInventiva S.A.FY202533.7% -66.3 pp-106.4 pp
FHTXFoghorn Therapeutics Inc.LTM Mar 202622.3% -77.7 pp-10.8 pp
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-17996.6% -16820.4 pp+19.0 pp
IMRXImmuneering CorporationFY2025— ——
AARDAardvark Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding BDTX) 67.3%-34.0 pp-6.4 pp

Competitors are the stored peer set for BDTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000070M
Cost of Revenue00437K0325K
Gross Profit00(437K)069.68M
Gross Margin————99.5%
Research & Development96.83M64.44M58.91M51.31M33.56M
Selling, General & Admin30.04M28.39M27.11M27.47M16.57M
Operating Expenses126.87M92.83M86.02M78.78M49.81M
Depreciation & Amortization205K508K437K343K325K
EBITDA(125.39M)(90.66M)(82.01M)(69.33M)22.69M
EBITDA Margin————32.4%
Operating Income(126.87M)(92.83M)(86.46M)(78.78M)19.87M
Operating Margin————28.4%
Interest Income3.46M2.03M1.92M2.18M4.06M
Interest Expense00000
Other Income / Expenses1.28M1.66M4.02M9.11M2.5M
Income Before Tax(125.6M)(91.17M)(82.44M)(69.68M)22.37M
Pre-Tax Margin————32.0%
Income Tax Expense00000
Net Income(125.6M)(91.17M)(82.44M)(69.68M)22.37M
Net Margin————32.0%
EPS (Basic)(3.47)(2.52)(1.88)(1.27)0.39
EPS (Diluted)(3.47)(2.52)(1.88)(1.27)0.39
Weighted Avg Shares36.19M36.23M43.95M55.03M56.87M
Weighted Avg Shares (Diluted)36.19M36.23M43.95M55.03M57.56M

Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

Intrinsic Alpha fair value

Locked

Current Price

$1.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.